Skip to main content
. 2018 Nov 30;2018(11):CD003177. doi: 10.1002/14651858.CD003177.pub4

Mita 2007.

Methods RCT, parallel, (EPA capsules vs nil), 2 years
Summary risk of bias: moderate to high
Participants Japanese type 2 diabetics
N: intervention. 40, control: 41 (analysed 30, 30)
Level of risk for CVD: moderate
Men: 53% intervention, 67% control
Mean age in years (SD): 59 (11.2) intervention 61.2 (8.4) control
Age range: not reported
Smokers: 40% intervention, 43% control
Hypertension: not reported
Medications taken by at least 50% of those in the control group: oral hypoglycemics
Medications taken by 20%‐49% of those in the control group: insulin, lipid lowering drugs, antihypertensives
Medications taken by some, but less than 20% of the control group: antithrombotics
Location: Japan
Ethnicity: 100% Japanese
Interventions Type: supplement (EPA oil capsules)
Comparison: EPA vs nil
Intervention: 1800 mg/d EPA EPADEL capsules (Mochida Pharmaceutical Co Ltd Japan)‐ 98% pure ethyl‐ester EPA (unclear how many caps). Dose: ˜1.8 g/d EPA
Control: no intervention
Compliance: checked during 3 month reviews throughout trial and 5 participants were excluded for poor compliance but no details on method or results
Length of intervention: mean 2.1 (0.2) years
Outcomes Main study outcome: progression of diabetic macroangiopathy measured by carotid intima‐media thickness and brachial‐ankle pulse wave velocity
Dropouts: 10 intervention, 11 control
Available outcomes: BMI, lipids, BP, HbA1c, cancer diagnosis
Response to contact: not yet attempted
Notes Blood pressure data not used as groups are different at baseline
Study funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Low risk Patients randomly divided into 2 groups matched for age and gender
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel (performance bias) 
 All outcomes High risk Open label
Blinding of outcome assessment (detection bias) 
 All outcomes Low risk Assessors of main study outcomes were blinded to the treatment
Incomplete outcome data (attrition bias) 
 All outcomes Low risk Dropout rate (26%) over 2 years. All dropouts explained, however, 5 were excluded for poor compliance but no clear predefined protocol for exclusion
Selective reporting (reporting bias) Unclear risk No protocol
Attention Low risk All participants had the same contact
Compliance Unclear risk Compliance measured but no clear methods or reported results
Other bias Low risk None noted
HHS Vulnerability Disclosure